Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Hiroshi Fujishima, Tomoko Hasunuma, Tetsuya Kawakita, Takuro Sekiya, Paul Gomes & David A. Hollander. (2021) Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study. Ocular Immunology and Inflammation 29:7-8, pages 1621-1626.
Read now
Read now
Hiroshi Nakatani, Paul Gomes, Ron Bradford, Qiang Guo, Eleonora Safyan & David A. Hollander. (2019) Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. Ocular Immunology and Inflammation 27:4, pages 622-631.
Read now
Read now
Edward J Meier, Gail L Torkildsen, Paul J Gomes & Mark C Jasek. (2018) Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. Clinical Ophthalmology 12, pages 2617-2628.
Read now
Read now
Eugene McLaurin, Mark Bergmann, Abhijit Narvekar, Adeniyi Adewale, Paul Gomes & Gail Torkildsen. (2017) Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clinical Ophthalmology 11, pages 1089-1097.
Read now
Read now
Ka Wai Kam, Li Jia Chen, Noel Wat & Alvin L. Young. (2017) Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. Ocular Immunology and Inflammation 25:5, pages 668-682.
Read now
Read now
Alexei Gonzalez-Estrada, Keerthi Reddy, Ves Dimov & Frank Eidelman. (2017) Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opinion on Pharmacotherapy 18:11, pages 1137-1143.
Read now
Read now
Joseph B Ciolino, Eugene B McLaurin, Nicholas P Marsico, Stacey L Ackerman, Julia M Williams, Linda Villanueva & David A Hollander. (2015) Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials. Clinical Ophthalmology 9, pages 765-772.
Read now
Read now
DeGaulle I Chigbu & Alissa M Coyne. (2015) Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis. Clinical Ophthalmology 9, pages 1215-1225.
Read now
Read now
Paul Gomes, Connie Slocum, Lisa M Smith & Mark B Abelson. (2015) Challenges faced in clinical trials for chronic allergic conjunctivitis. Expert Review of Ophthalmology 10:5, pages 509-518.
Read now
Read now
Mark B Abelson, Sirikishan Shetty, Michael Korchak, Salim I Butrus & Lisa M Smith. (2015) Advances in pharmacotherapy for allergic conjunctivitis. Expert Opinion on Pharmacotherapy 16:8, pages 1219-1231.
Read now
Read now
Paramdeep S Bilkhu, Shehzad A Naroo & James S Wolffsohn. (2015) Treatment of ocular allergies: nonpharmacologic, pharmacologic and immunotherapy. Expert Review of Ophthalmology 10:3, pages 257-266.
Read now
Read now
Articles from other publishers (15)
Akila KDr.Dr., Sriya SridharDr.Dr., Swetha SridharDr.Dr. & C.R. JayanthiDr.Dr.. (2022) “A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF ALCAFTADINE 0.25% VERSUS OLOPATADINE HYDROCHLORIDE 0.2% IN ALLERGIC CONJUNCTIVITIS AT A TERTIARY CARE HOSPITAL”. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, pages 34-37.
Crossref
Crossref
Rohan Bir Singh, Lingjia Liu, Ann Yung, Sonia Anchouche, Sharad K. Mittal, Tomas Blanco, Thomas H. Dohlman, Jia Yin & Reza Dana. (2021) Ocular redness – II: Progress in development of therapeutics for the management of conjunctival hyperemia. The Ocular Surface 21, pages 66-77.
Crossref
Crossref
Sawsan A. Abdel Razeq, Shimaa E. Abdel Aziz & Nermin S. Ahmed. (2021) Stability-indicating UPLC, TLC-densitometric and UV-spectrophotometric methods for alcaftadine determination. Journal of Chromatography B 1177, pages 122804.
Crossref
Crossref
Shruti Ayyappanavar, Sriya Sridhar, Kiran Kumar, CR Jayanthi, SureshBabu Gangasagara, BL Sujatha Rathod, B Preethi & Preeti Mittal. (2021) Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. Indian Journal of Ophthalmology 69:2, pages 257.
Crossref
Crossref
Snigdha Sen, Himanshu Kumar Yadav & Prerana Singh. (2020) A Comparative Study of Efficacy of Alcaftadine 0.25 % and Olopatadine 0.2 % in Allergic Conjunctivitis. Journal of Evidence Based Medicine and Healthcare 7:52, pages 3153-3158.
Crossref
Crossref
Rinky ThakurSachin KumarSanjay Kumar. (2020) Evaluation Of Prescribing Pattern For Various Types Of Allergic Conjunctivitis In Ophthalmology Outpatient Department Of Nalanda Medical College: A Tertiary Care Teaching Hospital Of Bihar. GLOBAL JOURNAL FOR RESEARCH ANALYSIS, pages 1-4.
Crossref
Crossref
Pushpendra ChotiyaDrDrArvind ChauhanDrDr. (2020) AN EFFICACY COMPARISON STUDY BETWEEN TOPICAL ANTI ALLERGIC DRUGS IN PATIENTS WITH ALLERGIC CONJUNCTIVITIS IN WESTERN RAJASTHAN. PARIPEX INDIAN JOURNAL OF RESEARCH, pages 22-24.
Crossref
Crossref
Vadlakonda Sruthi, ResuNeha Reddy, K Sowmini & NagurSharone Grace. (2020) To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. Indian Journal of Pharmacology 52:6, pages 476.
Crossref
Crossref
Sung Il Kim, Choul Yong Park, Gladys Fordjuor, Jong Heon Lee, Jong Soo Lee & Ji Eun Lee. (2019) Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. BMC Ophthalmology 19:1.
Crossref
Crossref
Shiyan Cao, Shining Cao, Aiwei Chen, Lanlan Yang & Yuan Chen. (2019) Comparing Efficacy and Safety of Olopatadine and Emedastine in
Patients with Allergic Conjunctivitis. International Journal of Pharmacology 15:3, pages 327-335.
Crossref
Crossref
Lakshey Dudeja, Anuja Janakiraman, Ishani Dudeja, Kaustubh Sane & Manohar Babu. (2019) Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. Indian Journal of Ophthalmology 67:9, pages 1400.
Crossref
Crossref
Warner Carr, Jack Schaeffer & Eric Donnenfeld. (2016) Treating Allergic Conjunctivitis: A Once-daily Medication that Provides 24-hour Symptom Relief. Allergy & Rhinology 7:2, pages ar.2016.7.0158.
Crossref
Crossref
Stacey Ackerman, Lisa M. Smith & Paulo J. Gomes. (2016) Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Therapeutic Advances in Chronic Disease 7:1, pages 52-67.
Crossref
Crossref
Paulo J. Gomes. (2014) Trends in prevalence and treatment of ocular allergy. Current Opinion in Allergy & Clinical Immunology 14:5, pages 451-456.
Crossref
Crossref
Eugene B. McLaurin, Nicholas P. Marsico, Stacey L. Ackerman, Joseph B. Ciolino, Julia M. Williams, Linda Villanueva & David A. Hollander. (2014) Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials. Advances in Therapy 31:10, pages 1059-1071.
Crossref
Crossref